GDC 0425

Drug Profile

GDC 0425

Alternative Names: GDC-0425; RG-7602

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 01 May 2014 Genentech completes a phase I trial in Lymphoma and Solid tumours (late-stage disease) in USA and France (NCT01359696)
  • 30 Jan 2014 Discontinued - Phase-I for Lymphoma and Solid tumours (late-stage disease) in USA and France (PO)
  • 17 Oct 2013 GDC 0425 is still in phase I trials for Solid tumours and Lymphoma (late-stage disease) in USA and France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top